Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

Phase 1

Completed

Conditions: Healthy Volunteer, Type 2 Diabetes

Interventions: Drug: Placebo
Drug: RO6799477

First Posted Date: 2014-06-16

Last Posted Date: 2017-06-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT02164266

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Other: Adalimumab Placebo
Drug: Adalimumab
Drug: Etrolizumab
Other: Etrolizumab Placebo

First Posted Date: 2014-06-16

Last Posted Date: 2021-07-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 358

Registration Number: NCT02163759

Locations: 🇵🇱
EMC Instytut Medyczny S.A., Wrocław, Poland
🇵🇱
AppleTreeClinics Sp. z o.o., Łódź, Poland
🇪🇪
Tartu University Hospital, Tartu, Estonia

and more 85 locations

A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: CMS
Drug: RO7033877
Drug: RO7033877 + CMS

First Posted Date: 2014-06-05

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT02156323

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

Not Applicable

Completed

Conditions: Type II Diabetes Mellitus

Interventions: Device: Accu-Chek Smart Pix readout Device
Device: Accu-Chek Smart Pix Software

First Posted Date: 2014-06-05

Last Posted Date: 2017-11-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 558

Registration Number: NCT02156349

Locations: 🇩🇪
Forschungsinstitut der Diabetes Akademie Mergentheim (FIDAM), Bad Mergentheim, Germany
🇩🇪
Diabetes- und Gesundheitszentrum Göttingen, Gottingen, Germany
🇩🇪
Diabetologicum Dresden, Dresden, Germany

and more 26 locations

An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer

Completed

Conditions: Ovarian Cancer

First Posted Date: 2014-05-30

Last Posted Date: 2014-05-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3

Registration Number: NCT02151370

A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

Phase 4

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Epoetin beta

First Posted Date: 2014-05-22

Last Posted Date: 2020-04-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT02145026

Locations: 🇹🇭
Siriraj Hospital; Division of Hematology, Department of Medicine, Bangkok, Thailand
🇹🇭
Thammasart Chalermprakiert Hospital, Thammasart Uni; Hematology, Pathumthani, Thailand
🇹🇭
Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine, Khon Kaen, Thailand

and more 7 locations

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: BMS-986089
Drug: Placebo matching with BMS-986089

First Posted Date: 2014-05-22

Last Posted Date: 2017-09-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 140

Registration Number: NCT02145234

Locations: 🇺🇸
Wcct Global, Llc, Cypress, California, United States

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Phase 3

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab Emtansine
Drug: Trastuzumab
Drug: Docetaxel

First Posted Date: 2014-05-21

Last Posted Date: 2017-03-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT02144012

An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma

Completed

Conditions: Malignant Melanoma

First Posted Date: 2014-05-21

Last Posted Date: 2017-06-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 403

Registration Number: NCT02143999

Locations: 🇮🇹
Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica, Chieti, Abruzzo, Italy
🇮🇹
IRCCS IST. Tumori Fondaz. Pascale; S.C. Oncologia Medica,Melanoma,Immunoterapia E Terapie Innovative, Napoli, Campania, Italy
🇮🇹
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy

and more 21 locations

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: 5-FU
Drug: Folinic acid
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Vanucizumab

First Posted Date: 2014-05-19

Last Posted Date: 2020-03-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 197

Registration Number: NCT02141295

Locations: 🇬🇧
Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom
🇺🇸
Fresno cCare, Fresno, California, United States
🇺🇸
Oncology Hematology Care Inc, Cincinnati, Ohio, United States

and more 36 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy